Summary

Effect of a clinical pharmacist on 30-day revisits following discharge from an emergency department: a randomized controlled clinical trial

Matías F. Martínez1, Luis Herrada2, Carolina Gutiérrez-Cáceres1, Sandra Espinoza-Muñoz1, Daniel Palma1, Marcela Jirón1


Affiliation of the authors

1Departamento de Ciencias y Tecnología Farmacéutica, Facultad de Ciencias Químicas y Farmacéuticas, Universidad de Chile, Santiago, Chile. 2Servicio de Urgencias, Hospital Clínico de la Universidad de Chile

DOI

Quote

Martínez MF, Herrada L, Gutiérrez-Cáceres C, Espinoza-Muñoz S, Palma D, Jirón M. Effect of a clinical pharmacist on 30-day revisits following discharge from an emergency department: a randomized controlled clinical trial. Emergencias. 2024;36:33-40

Summary

Objectives.

To evaluate a clinical pharmacist’s inclusion in emergency department (ED) care in terms of the effect on 30-day revisits after discharge from the ED and patient satisfaction.

Methods.

Randomized, controlled parallel-group pragmatic trial in a university hospital ED. Recruited patients were randomly assigned to a control group for standard care only or an intervention group to receive standard care plus the attention of a clinical pharmacist integrated into the care team to optimize the selection and evaluation of medications and provide pharmacotherapeutic education on the patient’s discharge. The primary outcome was unplanned revisits within 30 days after discharge because of the same complaint that led to the initial ED visit. Between-group differences were analyzed with Kaplan-Meier survival curves and log-rank tests. The association
between the intervention and time to the outcome event was explored with multivariate Cox proportional hazard regression analysis.

Results.

A total of 1001 patients were enrolled (intervention, 500; control, 501). Patients in both groups were similar. A majority were women (61.5%), and the median age (interquartile range) was 51 years (33-65 years). The pharmacist’s intervention significantly reduced the number of 30-day revisits to any ED: 25 (6.3%) revisited vs 66 (16.7%) in the control group. The adjusted hazard ratio (aHR) was 0.29 (95% CI, 0.17-0.50). Fifteen patients (3.0%) from the intervention group revisited the same ED vs 32 (6.5%) from the control group (aHR, 0.46 [95% CI, 0.24-0.87]). More patients expressed satisfaction in the intervention group (87.2%) than in the control group ( 83.2%) (P < .05).

Conclusions.

Including a clinical pharmacist in ED care substantially reduces the number of 30-day revisits and increases patient satisfaction.

 

More articles by the authors

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.